AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02955160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine
Study NCT02955160 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tdap
Description: Tetanus, diphtheria, and pertussis vaccine
Study NCT02947503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin TEVA 850 mg
Description: At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
Study NCT03245515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: specified dose on specified days
Study NCT03298074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, 500mg,po qd for continuous administration
Study NCT03298074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide,100mg, PO.QD，D1-D10, Q3W
Study NCT00625391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg medicinal starch pills daily
Study NCT00625391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea Polyphenols (GTP)
Description: 500 mg green tea polyphenols daily
Study NCT00625391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo+Tai Chi (TC)
Description: 500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
Study NCT00625391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTP+TC
Description: 500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
Study NCT01795976 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 T cells
Study NCT01795976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 60mg/kg/day day -7 and day -6
Study NCT01795976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given 25mg/m2 day -5 to day -1
Study NCT01795976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Interleukin 2 (IL2) immunotherapy given day 0 to day 6
Study NCT00693446 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day.
Study NCT03298074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide,100mg, PO.QD，D1-D10, Q3W
Study NCT00693446 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids.
Study NCT01754636 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01760616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Study NCT01059864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
Study NCT01059864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
Study NCT01059864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Placebo
Description: Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
Study NCT02183506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT02183506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT02183506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS
Study NCT00692185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
Study NCT04614350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Markman Biologics Microsurfaced ADM
Description: an ADM which has been scored (microsurfaced)
Study NCT04614350 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm
Description: AlloDerm tissue matrix
Study NCT00692185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
Study NCT04080141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple psychometric questionnaire
Description: At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
Study NCT04080141 — intervention group
Intervention type: PROCEDURE
Intervention: Clinical psychiatric examination
Description: At the time of first contact (T0) only women were subjected to psychiatric clinical examination
Study NCT04654598 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BPA levels
Description: BPA (bisphenol A) in urine, blood and follicle fluid samples
Study NCT01609218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Study NCT01609218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aqueous activated charcoal
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone/Prednisolone
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP16
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT00199082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine/Vindesine
Study NCT00199082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation (in specific conditions)
Study NCT01865474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: 1 DLBS1033 tablet 490 mg thrice daily for 2 months
Study NCT01865474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo tablet of DLBS1033
Description: 1 placebo tablet of DLBS1033 thrice daily for 2 months
Study NCT02134106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polymyxin B
Description: Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
Study NCT01699295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A+PAAC
Description: academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
Study NCT01699295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CON
Description: lessons taught by regular classroom teachers using traditional/regular sedentary lessons
Study NCT02854670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin patch
Description: After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
Study NCT02284945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open fixation
Study NCT02284945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Keyhole surgery
Study NCT04107116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program participants
Description: The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
Study NCT04107116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study NCT04107116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study NCT02267369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media-assisted fitness program
Description: Participants can register workshops online, track program participation, and receive promotional health messages online.
Study NCT02267369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network-assisted fitness program
Description: Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
Study NCT02267369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic fitness program
Description: Participants can register workshops online and track program participation.
Study NCT00469872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Context-focused compared to child-focused interventions
Study NCT00469872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Context-focused compared to child-focused interventions
Study NCT00720824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthetic and hypnotic distraction
Description: Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
Study NCT01274234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)
Description: The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
Study NCT03269539 — intervention group
Intervention type: OTHER
Intervention: MRI Imaging
Study NCT01350258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the conditioning regimen
Study NCT01350258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Part of the conditioning regimen
Study NCT01350258 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
Study NCT01350258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
Study NCT01350258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
Study NCT01350258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Description: One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.
Study NCT03370211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
Study NCT04505644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
Study NCT04505644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV lidocaine
Description: received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight \<70 kg.
Study NCT04505644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV saline infusion +Sham patch
Description: received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
Study NCT02905838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic e.max Abutment
Description: Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
Study NCT02905838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM CARES Abutment
Description: Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position.
Study NCT04194892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Administered SQ
Study NCT04452747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Dinoprostone system (Propess®)
Description: Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
Study NCT04452747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilatation balloon
Description: Labour will be induced using a cervix dilatation balloon as a first strategy
Study NCT05233501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: adjunctive application of low level laser therapy to non-surgical periodontal treatment
Study NCT05233501 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non-surgical periodontal treatment
Description: standart periodontal therapy
Study NCT05233501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: standart periodontal therapy
Study NCT02277249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin (transvaginal administration)
Description: Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
Study NCT02277249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin (transabdominal administration)
Description: Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
Study NCT01845831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
Study NCT01784367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vv-ECCO2R (Novalung GmbH, Germany)
Description: Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
Study NCT01295138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Lactulose liquid. 15mls twice daily
Study NCT02075294 — intervention group
Intervention type: DRUG
Intervention: Adefovir dipivoxil or Entecavir
Description: Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines
Study NCT04426175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting
Description: 2D and 3D cutting methods were randomly used in same subjects
Study NCT04317339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhigancao Tang granule
Description: Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
Study NCT04317339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zhigancao Tang placebo granule
Description: Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.